Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycodone/naloxone prolonged-release plus crisugabalin for cancer-related neuropathic pain
ChiCTR2600127459Phase 4Not yet recruiting
- Sponsor
- Xuzhou Central Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oxycodone + naloxone and crisugabalin besilate in bronchial carcinoma, liver cancer, gastric cancer (GC) and 3 more, sponsored by Xuzhou Central Hospital. Primary endpoint: Change in NRS and DN4 scores at Week 4 and pain response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
oxycodone + naloxonecrisugabalin besilate
03
Conditions
bronchial carcinomaliver cancergastric cancer (GC)colorectal cancer (CRC)Neuralgia
Beyond the preview
Go deeper on ChiCTR2600127459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127459.